Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG081821AC monotherapy in early to mid-stage Parkinson's disease
CTR20230400Phase 2Completed
- Sponsor
- Zhejiang Chunhe Pharmaceutical Technology
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing VG081821AC with Placebo (2 arms). Primary endpoint: Change from baseline in MDS-UPDRS Part III (motor examination) score at week 12. Started Feb 2023; status: completed.
02
Drugs
VG081821AC
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20230400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230400.